Daniel Deangelo
Hematology & Oncology · Boston, MANPI 1134104920
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $193,900 of the $275,953 with a category attached, or 70.3%. It is spread thinly across 28 manufacturers, the largest accounting for just 22.4%. Among hematology & oncology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 203 payments — averaging $1359.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$62K
- Novartis$51K
- Gilead$22K
- Amgen$19K
- Jazz Pharmaceuticals Inc.$14K
- Takeda Pharmaceuticals U.S.A., Inc.$12K
- plus $94K from 22 others
Across 357 payments — averaging $79,224 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$18.4M
- Novartis$5.9M
- Blueprint Medicines Corporation$1.5M
- Servier Bioinnovation$958K
- AbbVie$867K
- Adaptive Biotechnologies Corporation$140K
- plus $467K from 10 others
What the payments were for
- Consulting fees$193,90070%
- Speaking & faculty fees$71,63226%
- Travel & lodging$7,1463%
- Food & beverage$3,2721%
- Education$40%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 39 | $61,890 |
| Novartis | 19 | $51,493 |
| Gilead | 14 | $22,380 |
| Amgen | 12 | $19,325 |
| Jazz Pharmaceuticals Inc. | 8 | $14,111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $12,498 |
| Servier Pharmaceuticals LLC | 12 | $11,888 |
| E.r. Squibb & Sons, L.L.C. | 10 | $8,789 |
| Blueprint Medicines Corporation | 14 | $8,448 |
| Daiichi Sankyo Inc. | 6 | $6,894 |
| Adaptive Biotechnologies Corporation | 6 | $6,746 |
| Autolus Inc | 1 | $6,635 |
| GSK | 6 | $5,979 |
| AstraZeneca | 3 | $5,814 |
| Bristol Myers Squibb | 12 | $4,803 |
| Astellas Pharma US Inc | 1 | $4,563 |
| Incyte Corporation | 7 | $3,685 |
| Geron Corporation | 5 | $3,491 |
| Immunogen, Inc. | 2 | $2,940 |
| Sobi, Inc | 1 | $2,775 |
| Syndax Pharmaceuticals, Inc. | 2 | $2,408 |
| Merck | 1 | $2,240 |
| Agios Pharmaceuticals, Inc. | 2 | $2,221 |
| Intuitive Surgical | 6 | $1,152 |
| Rigel Pharmaceuticals, Inc. | 1 | $1,028 |
| CTI Biopharma Corp. | 1 | $900 |
| AbbVie | 1 | $830 |
| Pfizer Corporation Hong Kong Limited | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$275,953 in reported general payments places this provider in the 95th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AyvakitAvapritinib | 51 | $1,964,430 |
| JakafiRuxolitinib Phosphate | 103 | $1,631,381 |
| SprycelDasatinib | 42 | $503,414 |
| ScemblixAsciminib Hydrochloride | 22 | $439,198 |
| VonjoPacritinib Citrate | 18 | $402,485 |
| TibsovoIvosidenib | 12 | $351,860 |
| VenclextaVenetoclax | 27 | $202,469 |
| Imatinib Mesylate | 80 | $172,661 |
| Deferasirox | 19 | $3,444 |
| Hydroxyurea | 109 | $2,769 |
| Lidocaine | 11 | $532 |
| Acyclovir | 18 | $436 |
| Prednisone | 26 | $210 |
| Allopurinol | 19 | $184 |
| Furosemide | 12 | $115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Blueprint Medicines CorporationAyvakit | $8,448 | $1,964,43051 claims |
| Incyte CorporationJakafi | $3,685 | $1,631,381103 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $8,789 | $503,41442 claims |
| NovartisScemblix | $51,493 | $439,19822 claims |
| Servier Pharmaceuticals LLCTibsovo | $11,888 | $351,86012 claims |
| AbbVieVenclexta | $830 | $202,46927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 374 hematology & oncology providers in Massachusetts.
Other hematology & oncology in Boston
- David ScaddenBoston$2.6M
- Sara TolaneyBoston$799K
- Matthew DavidsBoston$693K
- Julio HajdenbergBoston$583K
- Paul RichardsonBoston$523K
- Seth WanderBoston$464K
- Corey CutlerBoston$454K
- Hanny Al-SamkariBoston$412K
- Rupal BhattBoston$380K
- Matthew Vander HeidenBoston$355K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.